The Pharmaceutical Journal examines personalised treatment to depression including P1vital® PReDicT Test which is being used in PReDicT clinical study across 5 European countries. To read the full […]
Following ECNP Congress where Catherine J. Harmer, DPhil talked about early change in emotional processing predicting antidepressant response, Clinical Psychiatry News discusses PReDicT study and the P1vital® PReDicT […]
University of Nottingham, MindTech article talks about PReDicT project and the P1vital® PReDicT Test which is being used in clinical study across 5 European countries: France, Germany, Spain, […]
Study Protocol have been published via Open Access, ‘The effects of using the PReDicT Test to guide the antidepressant treatment of depressed patients: study protocol for a randomised controlled trial’, with […]
Oxford Health NHS Foundation Trust about PReDicT Project discusses P1vital Products Limited and the P1vital® PReDicT Test which is being used in clinical study across 5 European countries. To […]
Oxford University article talks about PReDicT Project run by P1vital Products Limited and the P1vital® PReDicT Test which is being used in clinical study across 5 European countries: […]
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 696802. Horizon 2020 has a goal of ensuring that […]
To facilitate the organisation and management, the PReDicT Project is structured in workpackages (WPs) which together comprise the project. Each WP has a WP lead from P1vital […]
Following a successful UK primary care study, (funded by SBRI, NHS England) P1vital Ltd has secured €4m in funding from the EU Horizon 2020 SME programme to […]